Table 1

Characteristics of the seven enrolled patients before and after MSCT

	Patient number
	1	2	3	4	5	6	7
Age	33	27	26	27	41	24	25
Sex	M	M	F	M	F	M	F
Diagnosis	CD	CD	CD	CD	UC	UC	UC
Disease duration (m)	40	6	120	34	62	113	48
Extent of disease	Ileum and colon	Terminal ileum	Ileum and colon	colon	Pancolitis	Pancolitis	Pancolitis
Previous treatment	CS 5-ASA CYC Antibiotics	CS MTX SASP Etanercept	CS SASP CYC	CS SASP Infliximab Antibiotics	CS SASP MMF CYC 5-ASA	CS SASP 5-ASA	CS SASP 5-ASA
Therapies used within 3 months before MSCT	CS CYC Antibiotics	CS SASP	CS SASP	CS CYC	CS MMF CYC	5-ASA	CS SASP
Baseline CDAI/CAI score	223	335	295	378	8	10	9
Baseline EIS/EAI score	18.7	19.1	14.5	20.3	7	9	8
Concomitant medication	CS CYC	CS SASP	CS SASP	CS CYC	CS 5-ASA	5-ASA	CS SASP
CDAI/CAI score at 3 months after MSCT	187	140	126	284	2	5	5
EIS/EAI score after MSCT	NA	4.2 (4 months)	3 (3 months)	NA	5 (5 months)	9	NA
Adverse events	NA	NA	Face hot	NA	Insomnia	Low fever	NA

5-ASA, 5-aminosalicylic acid; CAI, Clinical Activity Index; CD, Crohn's disease; CDAI, Crohn's Disease Activity Index; CS, corticosteroids; CYC, cyclosporine; EAI, Endoscopic Activity Index; EIS, Endoscopic Index of Severity; m, month; MMF, mycophenolate mofetil; MSCT, mesenchymal stem cell transplantation; MTX, methotrexate; NA, not available; SASP, sulfasalazine; UC, ulcerative colitis.